Consistent with this, inhibition of mTORC1 by rapamycin promoted the expansion of the CD4+FoxP3+ Treg population and the suppression of Th17 cells, and was capable to decrease disease activity in patients with active SLE (63–65). This evidence concerns the gene CD4 and systemic lupus erythematosus.